Skip to content

19-255 -Trial of Study Medication as Monotherapy or Combination Therapy or Placebo in Women with Recurrent Cervical Cancer

Status: open

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Treatment for Cervical Cancer

Contact Us


This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms. Rather, the efficacy of each arm will be evaluated against its relevant historical controls as appropriate.


This trial is sponsored by Agenus.

Principle Investigator

    Providers Associated With This Trial

    Sub Investigators

    This link will open in a new tab or window.